QTORIN Rapamycin Gel for Microcystic Lymphatic Malformations

QTORIN Rapamycin Gel for Microcystic Lymphatic Malformations
75%64%53%Feb 17Feb 18Feb 19Feb 20Feb 21Feb 22Feb 23Feb 24Feb 25Feb 26Feb 27Feb 28Mar 1Mar 2Mar 3Mar 4Mar 5Mar 6Mar 7Mar 8Mar 9Mar 10Mar 11Mar 12Mar 13Mar 14Mar 15Mar 16Mar 17Mar 18Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29Mar 30Mar 31Apr 1Apr 2Apr 3Apr 4Apr 5Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 25May 21 • YES 62.0%May 22 • YES 62.8%May 23 • YES 63.5%May 24 • YES 64.7%May 25 • YES 65.1%
Palvella Therapeutics, Inc. ($PVLA)
No stock closeNo stock close$126.9$100.0$73.07Feb 17Feb 18Feb 19Feb 20Feb 21Feb 22Feb 23Feb 24Feb 25Feb 26Feb 27Feb 28Mar 1Mar 2Mar 3Mar 4Mar 5Mar 6Mar 7Mar 8Mar 9Mar 10Mar 11Mar 12Mar 13Mar 14Mar 15Mar 16Mar 17Mar 18Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27Mar 28Mar 29Mar 30Mar 31Apr 1Apr 2Apr 3Apr 4Apr 5Apr 6Apr 7Apr 8Apr 9Apr 10Apr 11Apr 12Apr 13Apr 14Apr 15Apr 16Apr 17Apr 18Apr 19Apr 20Apr 21Apr 22Apr 23Apr 24Apr 25Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 25Feb 17 • PVLA $80.09Feb 18 • PVLA $79.60Feb 19 • PVLA $82.33Feb 20 • PVLA $85.66Feb 23 • PVLA $87.84Feb 24 • PVLA $120.4
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
YESAccepted94% confidenceGPT-5.5 (OpenAI)
Question
Will this trial show a positive result on overall microcystic lymphatic malformations Investigator Global Assessment (mLM-IGA)?
Found
Outcome Date
Reviewed
Summary

Sponsor’s Phase 3 SELVA topline readout explicitly calls results positive and says the trial met the mLM-IGA primary endpoint at Week 24 with statistically significant improvement (+2.13; p<0.001), with most completers improved.

Sources
Sponsorir.palvellatx.com
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN rapamycin in Microcystic LMs

Positive topline results: Phase 3 SELVA met its primary endpoint on mLM-IGA at Week 24; mean improvement +2.13, p<0.001, and 95% of completers improved.

Stats
Latest Run
Model
GPT-5.5 (OpenAI)
Runs
1 run